Compare Raymond James Financial, Inc. (RJF) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs BIO-TECHNE Corp — how do they compare? Raymond James Financial, Inc. trades at $158.14 (market cap $30.25B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Raymond James Financial, Inc. is far larger — about 2.7× BIO-TECHNE Corp's market cap, and Raymond James Financial, Inc. pays the higher dividend (1.37%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and BIO-TECHNE Corp for 63 Days on average.
| RJF | TECH | |
|---|---|---|
Market Cap | $30.25B | $11.37B |
Volume | 1,288,635 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $181.18 | $72.61 |
52-Week Low | $140.89 | $43.31 |
Typical Hold Time | 74 Days | 63 Days |
Enterprise Value | $24.12B | $11.40B |
Dividend Yield | 1.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $158.6, down 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.14, and maintains solid fundamentals including a P/E of 13.71 and ROE of 18.48%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical weakness and high investing cash outflows pose risks. Revenue growth and margin stability support long-term value, though market volatility and expense pressures remain concerns for investors.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
